TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12854145

Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesorectal excision (LTME) with preservation of anal sphincter
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Laparoscopic low anterior resection (LLAR)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Laparoscopic ultralow anterior resection (LULAR)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Laparoscopic coloanal anastomoses (LCAA)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Postoperative recovery
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Mean operating time
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Mean operative blood loss
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Mean hospital stay
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Interoperative complications
Number of subjects: 82
Study: 11195876

Group type: EXPERIMENTAL
Intervention: Manual lymph drainage (10 treatments)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (conventional treatment with exercises, movement, oedema control, and education)
Number of subjects: 26
Study: 9316510

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study: 8402758

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 150

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 150
Study: 3780825

Group type: EXPERIMENTAL
Intervention: Oral high-dose metoclopramide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous metoclopramide
Number of subjects: 12
Study: 29972535

Group type: EXPERIMENTAL
Intervention: Ear protectors
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no ear protectors)
Number of subjects: 12
Study: 29931843

Group type: EXPERIMENTAL
Intervention: Ligustrazine hydrochloride injection (LHI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional treatment (group C)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal control group (group N)
Number of subjects: 22
Study: 24807158

Group type: EXPERIMENTAL
Intervention: Chemotherapy (4 courses intravenous carboplatin day 1 and oral vinorelbine day 1 and 8, at 3‐week intervals)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (CRT) (radiotherapy with fractionation 42 Gy/15 starting at the second chemotherapy course)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (CRT)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Chemotherapy (without CRT)
Number of subjects: 188
Study: 22452559

Group type: EXPERIMENTAL
Intervention: 1-mg nasal nicotine spray (0.5 mg each nostril)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (pepper) spray
Number of subjects: 19
Study: 19695854

Group type: EXPERIMENTAL
Intervention: Simvastatin/Fluvastatin treatment for 16 weeks
Number of subjects: 20
Study: 18681363

Group type: EXPERIMENTAL
Intervention: IUI with COH
Number of subjects: 253

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 253
Study: 15955040

Group type: EXPERIMENTAL
Intervention: Epilepsy patients with migraine (EM group)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Epilepsy patients without migraine (E group)
Number of subjects: 115
Study: 12600905

Group type: EXPERIMENTAL
Intervention: Vitamin E (136 IU) plus slow-release vitamin C (250 mg) twice daily
Number of subjects: 520
Study: 10536636

Group type: EXPERIMENTAL
Intervention: Binary content checklist
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Global process rating
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Standardized patient interviews
Number of subjects: 42
Study: 9102014

Group type: EXPERIMENTAL
Intervention: Minilaparotomy (ML)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional transabdominal approach (CTA)
Number of subjects: 0
Study: 1856405

Group type: EXPERIMENTAL
Intervention: Heart failure group
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Heart failure group with three-vessel coronary artery disease
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Heart failure group without coronary artery disease
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Heart failure group who underwent surgical revascularization
Number of subjects: 284
Study: 6406886

Group type: EXPERIMENTAL
Intervention: Personal educational visits by clinical pharmacists and mailed 'unadvertisements'
Number of subjects: 435

Group type: COMPARATOR
Intervention: Mailed print materials only
Number of subjects: 435
Study: 30850024

Group type: EXPERIMENTAL
Intervention: PBL assessment rating scale of 12 different criteria on a six-point scale
Number of subjects: 181
Study: 28274210

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) starting within 4 weeks after randomization (Intervention Group, IG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control (Control Group, CG) starting PR 20 weeks after randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 0
Study: 26641853

Group type: EXPERIMENTAL
Intervention: Surgical discectomy
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Nonoperative care
Number of subjects: 1244
Study: 25112923

Group type: EXPERIMENTAL
Intervention: Patients' beliefs regarding symptoms associated with ulceration, understanding of ulceration, and perceived personal control over ulceration.
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Baseline foot self-care behaviours (week 0)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Age and ulcer size
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Interventions aimed at modifying illness beliefs
Number of subjects: 169
Study: 22287037

Group type: EXPERIMENTAL
Intervention: FR-aspirin 650 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FR-aspirin 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-aspirin 650 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-aspirin 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19865059

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of enoxaparin sodium and bed rest (Group B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of enoxaparin sodium and thigh-length compression stockings (Group C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of enoxaparin sodium and pneumatic compression (Group D)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (Group A)
Number of subjects: 48
Study: 17526857

Group type: EXPERIMENTAL
Intervention: Emtricitabine in combination with stavudine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine in combination with famciclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine in combination with zidovudine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine in combination with zidovudine glucuronide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emtricitabine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stavudine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Famciclovir alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine glucuronide alone
Number of subjects: 0
Study: 14504156

Group type: EXPERIMENTAL
Intervention: Intrathecal tramadol 25 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline 0.5 ml
Number of subjects: 64
Study: 10476732

Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: mebendazole
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: further chemotherapy cycles
Number of subjects: 448

Group type: COMPARATOR
Intervention: control group (not specified)
Number of subjects: 448
Study: 8927674

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Lithium alone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lithium plus neuroleptics
Number of subjects: 41
Study: 1798845

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6645218

Group type: EXPERIMENTAL
Intervention: Conventional hemodialysis with dialysate sodium concentration 7% below predialysis serum concentration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Conventional hemodialysis with dialysate sodium concentration equal to predialysis serum concentration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High sodium dialyses with dialysate sodium concentration 7% above predialysis serum concentration
Number of subjects: 5
Study: 30942031

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with prednisone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 48
Study: 28056917

Group type: EXPERIMENTAL
Intervention: Fulranumab 9 mg administered subcutaneously at weeks 1, 5, and 9
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously at weeks 1, 5, and 9
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fulranumab 9 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 25001267

Group type: EXPERIMENTAL
Intervention: Intervention group received a 20 stipend monthly and engaged in social/leisure activities for 2 hours weekly over a 9-month period.
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group received a 20 monthly stipend and engaged in a weekly social/leisure activity.
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study: 23959669

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (Healthy Volunteers)
Number of subjects: 22
Study: 21613452

Group type: EXPERIMENTAL
Intervention: Formula with 8 g/L of a specific prebiotic mixture (short‐chain galacto‐oligosaccharides and long‐chain fructo‐oligosaccharides, ratio 9:1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Formula containing the same amount of maltodextrin (placebo)
Number of subjects: 20
Study: 19656409

Group type: EXPERIMENTAL
Intervention: Meltdown
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16368344

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting with cardiopulmonary bypass (CABG-CPB)
Number of subjects: 40
Study: 16219018

Group type: EXPERIMENTAL
Intervention: Exercise (EX) group (n=15) - supervised exercise twice a week for 12 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (CO) group (n=14)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Exercise (EX) group (n=15) - increase in pedometer activity
Number of subjects: 29
Study: 10692984

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/day
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day and 150 mg/day
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 8741209

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 1 mg/kg or 4 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Berberine 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinic acid 2 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetracycline (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bioflorin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose short-chain polymers with anthracene-9-carboxylic acid (A9C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandins (PGs)
Number of subjects: 0
Study: 1914797

Group type: COMPARATOR
Intervention: Soluble human insulin (Actrapid HM U-100)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AspB10
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AspB9, GluB27
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AspB28
Number of subjects: 6
Study: 7121133

Group type: EXPERIMENTAL
Intervention: Mexiletine (200 mg three times per day)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Betahistidine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 5
Study: 30676224

Group type: EXPERIMENTAL
Intervention: Simulated Horseback Riding (SHR) exercises for 30 minutes, 2 days per week for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Stabilization (STB) exercises for 30 minutes, 2 days per week for 8 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Simulated Horseback Riding (SHR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Stabilization (STB)
Number of subjects: 48
Study: 31278907

Group type: EXPERIMENTAL
Intervention: HFNC group (O2 [30-60 L/minute] via HFNC)
Number of subjects: 1994

Group type: COMPARATOR
Intervention: Nasal cannula group (O2 [2 L/minute] via nasal cannula)
Number of subjects: 1994
Study: 28424045

Group type: EXPERIMENTAL
Intervention: ModiMedDiet (modified Mediterranean diet)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Social support control group
Number of subjects: 67
Study: 26711786

Group type: EXPERIMENTAL
Intervention: MABC subgroup
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: MABC subgroup with positive HSP27 expression
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: MABC subgroup with positive GCDFP15 expression
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: MABC subgroup with HSP27 and GCDFP15 co-expression
Number of subjects: 158
Study: 25359007

Group type: EXPERIMENTAL
Intervention: Habit-formation intervention for child-feeding goals (giving fruit and vegetables, water, healthy snacks) over four fortnightly home visits
Number of subjects: 57
Study: 22515513

Group type: EXPERIMENTAL
Intervention: HD203 (25 mg/mL, administered subcutaneously)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Enbrel® (25 mg/mL, administered subcutaneously)
Number of subjects: 37
Study: 20618779

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1% chlorhexidine used for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dentifrice without chlorhexidine
Number of subjects: 0
Study: 18949318

Group type: EXPERIMENTAL
Intervention: Thrombocytopenic patients (TCP)
Number of subjects: 86
Study: 16212294

Group type: EXPERIMENTAL
Intervention: LASIK surgery
Number of subjects: 5081
Study: 11847596

Group type: EXPERIMENTAL
Intervention: Surface-modified CPB circuit (SMA)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (unmodified CPB circuit)
Number of subjects: 122
Study: 10625522

Group type: EXPERIMENTAL
Intervention: SINGLE meal pre-load (served as a single meal)
Number of subjects: 8

Group type: COMPARATOR
Intervention: MULTI meal pre-load (divided into five equal portions served hourly)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SINGLE meal pre-load
Number of subjects: 8

Group type: COMPARATOR
Intervention: MULTI meal pre-load
Number of subjects: 8
Study: 8540510

Group type: EXPERIMENTAL
Intervention: OM 20 mg once daily for 4 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: OM 40 mg once daily for 4 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: OM 20 mg daily for 12 months
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: OM 20 mg alternate days for 12 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 180
Study: 2023715

Group type: EXPERIMENTAL
Intervention: D15 panel test
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: desaturated D15 test
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Visual inspection
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: CDV analysis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Quantitative scoring techniques
Number of subjects: 99
Study: 31839279

Group type: EXPERIMENTAL
Intervention: Usual care plus oseltamivir
Number of subjects: 3266

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3266
Study: 31227530

Group type: EXPERIMENTAL
Intervention: Double balloon catheter for 12 hours with oxytocin after 6 hours
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vaginal prostaglandin for 24 hours followed by oxytocin infusion alone
Number of subjects: 80
Study: 29212681

Group type: EXPERIMENTAL
Intervention: Highly cross‐linked polyethylene (XLPE)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ultra‐high molecular weight polyethylene (UHMWPE)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ceramic‐on‐ceramic (CoC)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All three bearing groups
Number of subjects: 91
Study: 25961781

Group type: EXPERIMENTAL
Intervention: BMS-820836 flexible dose (0.5-2 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-820836 fixed dose (1 mg/d or greater)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuation of duloxetine (60 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-820836 (1 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-820836 (2 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuation group
Number of subjects: 0
Study: 23139259

Group type: EXPERIMENTAL
Intervention: P + CRT
Number of subjects: 68

Group type: COMPARATOR
Intervention: CRT
Number of subjects: 68
Study: 21764215

Group type: EXPERIMENTAL
Intervention: Active TMS (4000 pulses at 10 Hz for 10 sessions over 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 20
Study: 19298914

Group type: EXPERIMENTAL
Intervention: Bivalirudin alone
Number of subjects: 13819

Group type: COMPARATOR
Intervention: Heparin and glycoprotein IIb/IIIa inhibitors
Number of subjects: 13819
Study: 17668529

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.3%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tazarotene cream 0.05%
Number of subjects: 0
Study: 15500492

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 706

Group type: COMPARATOR
Intervention: Extra midazolam
Number of subjects: 706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study: 11749817

Group type: EXPERIMENTAL
Intervention: Huangqi Jianzhong Tang (HQJZT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9635328

Group type: EXPERIMENTAL
Intervention: Experimental group (amount of practice received)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (amount of practice received)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Experimental group (alpha power increase)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (alpha power increase)
Number of subjects: 83
Study: 8049053

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Face mask and Guedel oral airway (FM‐OA)
Number of subjects: 50
Study: 3289675

Group type: EXPERIMENTAL
Intervention: terodiline 25 mg bd
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: emepronium bromide 200 mg tds
Number of subjects: 20
Study: 31883255

Group type: EXPERIMENTAL
Intervention: 5% green tea mouthwash
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 20% green tea with xylitol mouthwash
Number of subjects: 64
Study: 27998961

Group type: EXPERIMENTAL
Intervention: Trastuzumab alone followed by chemotherapy at disease progression (Arm A)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Upfront trastuzumab plus chemotherapy (Arm B)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Patients without visceral disease in Arm A
Number of subjects: 175

Group type: COMPARATOR
Intervention: Patients without visceral disease in Arm B
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Overall survival for both arms
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 175
Study: 25710507

Group type: EXPERIMENTAL
Intervention: CXL treatment (0.1% riboflavin drops and UV-A irradiation at 365 nm for 30 minutes)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CXL treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard medical treatment (Control group)
Number of subjects: 32
Study: 23525597

Group type: EXPERIMENTAL
Intervention: Stable light/occasional smokers
Number of subjects: 3521

Group type: EXPERIMENTAL
Intervention: Accelerating smokers
Number of subjects: 3521

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 3521

Group type: EXPERIMENTAL
Intervention: Stable light/occasional smokers and accelerating smokers
Number of subjects: 3521

Group type: EXPERIMENTAL
Intervention: Accelerating smoking trajectory group
Number of subjects: 3521
Study: 21345638

Group type: EXPERIMENTAL
Intervention: Filter-leukoreduced platelet transfusions
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: UV-B-irradiated platelet transfusions
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard platelet transfusions
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Antibody persistence evaluation
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Type of platelets transfused during the trial
Number of subjects: 145
Study: 18679064

Group type: EXPERIMENTAL
Intervention: Granulocyte and monocyte/macrophage adsorptive apheresis (GMCAP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Leukocytapheresis (LCAP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both GMCAP and LCAP
Number of subjects: 39
Study: 16441800

Group type: EXPERIMENTAL
Intervention: 10 mg of dexamethasone
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2 mL of saline
Number of subjects: 72
Study: 12680422

Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10811673

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m(2) given as a 1‐hour intravenous infusion every 3 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m(2) given as a bolus injection every 3 weeks
Number of subjects: 86